Literature DB >> 9233613

Viral regulation of CD95 expression and apoptosis in T lymphocytes.

S Sieg1, Y Huang, D Kaplan.   

Abstract

T lymphocyte apoptosis has been observed in vivo in association with viral infections. One mechanism known to mediate T cell apoptosis is the CD95 (Fas/APO-1) Ag apoptotic pathway. CD95 is a cell surface protein that is expressed on activated T cells and is capable of relaying an intracellular apoptotic signal upon binding with CD95 ligand. CD95-dependent apoptosis has been shown to be involved in the homeostatic control of peripheral T cell numbers; however, the functional significance of the CD95 apoptotic pathway in the context of viral infections has not been clearly elucidated. We show that exposure to a variety of viral pathogens causes enhanced CD95 expression in naive peripheral blood cell T lymphocytes without leading to enhanced susceptibility to CD95-dependent apoptosis. Productive viral infection was not required for this effect. Furthermore, using a T cell line and the K562 tumor cell line, we demonstrate that cells normally resistant to CD95-mediated killing become susceptible when productively infected with virus in a manner that does not rely on increased CD95 surface expression. These findings demonstrate a regulatory influence of viral infection on CD95 expression and activity and suggest that in addition to having a role in T cell homeostasis, the CD95 apoptotic pathway might also function to eliminate virus-infected T cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9233613

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Elevated serum-soluble Fas ligand in histiocytic necrotizing lymphadenitis.

Authors:  K Kato; K Ohshima; K Anzai; J Suzumiya; M Kikuchi
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

2.  Cytomegalovirus infection in infants with autoimmune lymphoproliferative syndrome (ALPS).

Authors:  P D Arkwright; F Rieux-Laucat; F Le Deist; R F Stevens; B Angus; A J Cant
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

3.  Expansion of Stem Cell-Like CD4+ Memory T Cells during Acute HIV-1 Infection Is Linked to Rapid Disease Progression.

Authors:  Jernej Pušnik; Michael A Eller; Boonrat Tassaneetrithep; Bruce T Schultz; Leigh Anne Eller; Sorachai Nitayaphan; Josphat Kosgei; Lucas Maganga; Hannah Kibuuka; Galit Alter; Nelson L Michael; Merlin L Robb; Hendrik Streeck
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

4.  Impaired growth and elevated fas receptor expression in PIGA(+) stem cells in primary paroxysmal nocturnal hemoglobinuria.

Authors:  R Chen; S Nagarajan; G M Prince; U Maheshwari; L W Terstappen; D R Kaplan; S L Gerson; J M Albert; D E Dunn; H M Lazarus; M E Medof
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

5.  Apoptosis mediated by Fas but not tumor necrosis factor receptor 1 prevents chronic disease in mice infected with murine cytomegalovirus.

Authors:  M Fleck; E R Kern; T Zhou; J Podlech; W Wintersberger; C K Edwards; J D Mountz
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

6.  The role of in vitro-induced lymphocyte apoptosis in feline immunodeficiency virus infection: correlation with different markers of disease progression.

Authors:  E Holznagel; R Hofmann-Lehmann; C M Leutenegger; K Allenspach; S Huettner; U Forster; E Niederer; H Joller; B J Willett; U Hummel; G L Rossi; J Schüpbach; H Lutz
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

7.  Activation and evasion of innate antiviral immunity by herpes simplex virus.

Authors:  Jesper Melchjorsen; Sampsa Matikainen; Søren R Paludan
Journal:  Viruses       Date:  2009-11-05       Impact factor: 5.048

8.  Fas ligand-mediated lysis of self bystander targets by human papillomavirus-specific CD8+ cytotoxic T lymphocytes.

Authors:  M J Smyth; E Krasovskis; R W Johnstone
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.